Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

Mario Tiribelli; Roberto Latagliata; Luigiana Luciano; Fausto Castagnetti; Antonella Gozzini; Giovanna Rege Cambrin; Mario Annunziata; Fabio Stagno; Patrizia Pregno; Francesco Albano; Elisabetta Abruzzese; Pellegrino Musto; Enrico Montefusco; Carmen Fava; Renato Fanin; Fabrizio Pane; Gianantonio Rosti; Massimo Breccia; Giuliana Alimena; Paolo Vigneri

doi:10.1007/s00277-012-1591-2

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

Mario Tiribelli, Roberto Latagliata, Luigiana Luciano, Fausto Castagnetti, Antonella Gozzini, Giovanna Rege Cambrin, Mario Annunziata, Fabio Stagno, Patrizia Pregno, Francesco Albano, Elisabetta Abruzzese, Pellegrino Musto, Enrico Montefusco, Carmen Fava, Renato Fanin, Fabrizio Pane, Gianantonio Rosti, Massimo Breccia, Giuliana Alimena, Paolo Vigneri

IRCCS Centro di Riferimento Oncologico della Basilicata (CROB)

Research output: Contribution to journal › Article › peer-review

Abstract

To assess the impact of BCR-ABL kinase domain mutations on dasatinib response in elderly chronic myeloid leukemia (CML) patients, we analyzed the outcome of 76 individuals aged >60 affected by imatinib-resistant chronic-phase CML. We found that 36 cases (47 %) displayed mutations before dasatinib. Compared to non-mutated patients, subjects with point mutations had a worse response to dasatinib, with significantly lower rates of complete cytogenetic response (57 vs 32 %), higher percentage of primary resistance (16/36 vs 6/40) and a trend towards a shorter median event-free survival. Our data suggest that, in elderly patients, detection of BCR-ABL mutations negatively affects response to dasatinib.

Original language	English
Pages (from-to)	179-183
Number of pages	5
Journal	Annals of Hematology
Volume	92
Issue number	2
DOIs	https://doi.org/10.1007/s00277-012-1591-2
Publication status	Published - Jan 2013

Keywords

BCR-ABL mutations
CML
Dasatinib
Elderly patients
Imatinib resistance

ASJC Scopus subject areas

Hematology

Access to Document

10.1007/s00277-012-1591-2

Cite this

Tiribelli, M., Latagliata, R., Luciano, L., Castagnetti, F., Gozzini, A., Cambrin, G. R., Annunziata, M., Stagno, F., Pregno, P., Albano, F., Abruzzese, E., Musto, P., Montefusco, E., Fava, C., Fanin, R., Pane, F., Rosti, G., Breccia, M., Alimena, G., & Vigneri, P. (2013). Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. Annals of Hematology, 92(2), 179-183. https://doi.org/10.1007/s00277-012-1591-2

Tiribelli, M, Latagliata, R, Luciano, L, Castagnetti, F, Gozzini, A, Cambrin, GR, Annunziata, M, Stagno, F, Pregno, P, Albano, F, Abruzzese, E, Musto, P, Montefusco, E, Fava, C, Fanin, R, Pane, F, Rosti, G, Breccia, M, Alimena, G & Vigneri, P 2013, 'Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia', Annals of Hematology, vol. 92, no. 2, pp. 179-183. https://doi.org/10.1007/s00277-012-1591-2

@article{1599fd9c3f4a41c1913f749221c74c00,

title = "Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia",

abstract = "To assess the impact of BCR-ABL kinase domain mutations on dasatinib response in elderly chronic myeloid leukemia (CML) patients, we analyzed the outcome of 76 individuals aged >60 affected by imatinib-resistant chronic-phase CML. We found that 36 cases (47 %) displayed mutations before dasatinib. Compared to non-mutated patients, subjects with point mutations had a worse response to dasatinib, with significantly lower rates of complete cytogenetic response (57 vs 32 %), higher percentage of primary resistance (16/36 vs 6/40) and a trend towards a shorter median event-free survival. Our data suggest that, in elderly patients, detection of BCR-ABL mutations negatively affects response to dasatinib.",

keywords = "BCR-ABL mutations, CML, Dasatinib, Elderly patients, Imatinib resistance",

author = "Mario Tiribelli and Roberto Latagliata and Luigiana Luciano and Fausto Castagnetti and Antonella Gozzini and Cambrin, {Giovanna Rege} and Mario Annunziata and Fabio Stagno and Patrizia Pregno and Francesco Albano and Elisabetta Abruzzese and Pellegrino Musto and Enrico Montefusco and Carmen Fava and Renato Fanin and Fabrizio Pane and Gianantonio Rosti and Massimo Breccia and Giuliana Alimena and Paolo Vigneri",

year = "2013",

month = jan,

doi = "10.1007/s00277-012-1591-2",

language = "English",

volume = "92",

pages = "179--183",

journal = "Revue d'h{\'e}matologie",

issn = "0939-5555",

publisher = "Springer Verlag",

number = "2",

}

TY - JOUR

T1 - Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

AU - Tiribelli, Mario

AU - Latagliata, Roberto

AU - Luciano, Luigiana

AU - Castagnetti, Fausto

AU - Gozzini, Antonella

AU - Cambrin, Giovanna Rege

AU - Annunziata, Mario

AU - Stagno, Fabio

AU - Pregno, Patrizia

AU - Albano, Francesco

AU - Abruzzese, Elisabetta

AU - Musto, Pellegrino

AU - Montefusco, Enrico

AU - Fava, Carmen

AU - Fanin, Renato

AU - Pane, Fabrizio

AU - Rosti, Gianantonio

AU - Breccia, Massimo

AU - Alimena, Giuliana

AU - Vigneri, Paolo

PY - 2013/1

Y1 - 2013/1

N2 - To assess the impact of BCR-ABL kinase domain mutations on dasatinib response in elderly chronic myeloid leukemia (CML) patients, we analyzed the outcome of 76 individuals aged >60 affected by imatinib-resistant chronic-phase CML. We found that 36 cases (47 %) displayed mutations before dasatinib. Compared to non-mutated patients, subjects with point mutations had a worse response to dasatinib, with significantly lower rates of complete cytogenetic response (57 vs 32 %), higher percentage of primary resistance (16/36 vs 6/40) and a trend towards a shorter median event-free survival. Our data suggest that, in elderly patients, detection of BCR-ABL mutations negatively affects response to dasatinib.

AB - To assess the impact of BCR-ABL kinase domain mutations on dasatinib response in elderly chronic myeloid leukemia (CML) patients, we analyzed the outcome of 76 individuals aged >60 affected by imatinib-resistant chronic-phase CML. We found that 36 cases (47 %) displayed mutations before dasatinib. Compared to non-mutated patients, subjects with point mutations had a worse response to dasatinib, with significantly lower rates of complete cytogenetic response (57 vs 32 %), higher percentage of primary resistance (16/36 vs 6/40) and a trend towards a shorter median event-free survival. Our data suggest that, in elderly patients, detection of BCR-ABL mutations negatively affects response to dasatinib.

KW - BCR-ABL mutations

KW - CML

KW - Dasatinib

KW - Elderly patients

KW - Imatinib resistance

UR - http://www.scopus.com/inward/record.url?scp=84872284681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872284681&partnerID=8YFLogxK

U2 - 10.1007/s00277-012-1591-2

DO - 10.1007/s00277-012-1591-2

M3 - Article

C2 - 23053188

AN - SCOPUS:84872284681

SN - 0939-5555

VL - 92

SP - 179

EP - 183

JO - Revue d'hématologie

JF - Revue d'hématologie

IS - 2

ER -

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this